Evidence map›Paper›PMID 34607954›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Ye He, Joshua Rivera, Miklos Diossy, Haohui Duan, Christian Bowman-Colin, Rachel Reed, Rebecca Jennings, Jesse Novak, Stevenson V Tran, Elizabeth F Cohen and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Effects ofHeliyon · 2024
    Article
  3. Article
  4. Sequential Inhibition of PARP and BET as a Rational Therapeutic Strategy for Glioblastoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 3 countries.

Ye HeDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215.
Joshua RiveraCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA 02125.
Miklos DiossyDepartment of Statistics, Danish Cancer Society Research Center, Copenhagen, 2100, Denmark.
Haohui DuanCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA 02125.
Christian Bowman-ColinDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215.
Rachel ReedDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215.
Rebecca JenningsDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, 02215.
Jesse NovakDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, 02215.
Stevenson V TranCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA 02125.
Elizabeth F CohenDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215.
David SzutsInstitute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, 1117, Hungary.ORCID 0000-0001-7985-0136
Anita Giobbie-HurderDivision of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215.
Roderick T BronsonDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, 02215.
Adam J BassDivision of Hematology and Oncology, Columbia University/Herbert Irving Comprehensive Cancer Center, New York, NY 10032.
Sabina SignorettiDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, 02215.
Zoltan SzallasiDepartment of Statistics, Danish Cancer Society Research Center, Copenhagen, 2100, Denmark.
David M LivingstonDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215; david_livingston@dfci.harvard.edu Shailja.Pathania@umb.edu.
Shailja PathaniaCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA 02125; david_livingston@dfci.harvard.edu Shailja.Pathania@umb.edu.ORCID 0000-0001-8974-6420
Dana-Farber Cancer Institute · USBrigham and Women's Hospital · USUniversity of Massachusetts Boston · USBoston Children's Hospital · USColumbia University Irving Medical Center · USInstitute of Molecular Life Sciences · HU

Funding

Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Wanling Xie · 2003 to 2026
$53.4M
Tissue and Pathology CoreP50CA168504 · NCI · DANA-FARBER CANCER INST · PI MYLES A BROWN · 2013 to 2026
$30.1M
Deciphering the mechanism underlying BRCA1 breast cancer developmentR35CA242143 · NCI · DANA-FARBER CANCER INST · PI LIVINGSTON, DAVID MORSE · 2019 to 2021
$3.0M
NCI NIH HHS P50 CA101942NCI NIH HHS P50 CA168504NCI NIH HHS R35 CA242143
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

4-Nitroquinoline-1-oxideAnimalsBRCA1 ProteinCell Line, TumorCell Transformation, NeoplasticCheckpoint Kinase 1Disease Models, AnimalEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaFemaleGerm-Line MutationHeterozygoteHumansLoss of HeterozygosityMaleMice4-Nitroquinoline-1-oxideBRCA1 ProteinBRCA1 protein, humanCheckpoint Kinase 1Chek1 protein, mouseTP53 protein, humanTrp53bp1 protein, mouseTumor Suppressor p53-Binding Protein 1Tumor Suppressor Protein p53BRCA1haploinsufficiencymouse modelreplication stress

Identifiers

PMID34607954
PMCPMC8521688
OpenAlexW3204898899

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.